CDK9-IN-39
CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC50 of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer [1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
O=C(NC1=CC(C2=CC=C(C=C2OC(C)C)F)=CC=N1)NC3=CC(C(N4CCN(CC4)C)=O)=CC=C3
Molecular Formula
C27H30FN5O3
Molecular Weight
491.56
References & Citations
[1]Xu J, et al. Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In Vivo. J Med Chem. 2025 Jun 12;68 (11) :11586-11605.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Rabbit Polyclonal HR6A/UBE2A Antibody [HRP]](https://cdn.genprice.uk/genprice/uk/genprice3.webp)
